Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A 21-amino acid peptide encoded within the mitochondrial genome — one of the first mitochondria-derived peptides (MDPs) discovered. Humanin levels decline with age and are associated with longevity in centenarian offspring. Studied for neuroprotection, metabolic health, and cardiovascular protection.
A coenzyme found in all living cells that plays a central role in energy metabolism and cellular repair. NAD+ levels decline significantly with age. Injectable NAD+ and its precursors (NMN, NR) have become widely used in longevity and anti-aging protocols.
Binds to multiple receptors including gp130, FPRL1, and intracellular IGFBP-3. Activates STAT3 and AMPK signaling pathways. Inhibits neuronal apoptosis, reduces inflammation, improves insulin sensitivity, and protects against ischemic injury. Acts as a stress-response signal from mitochondria to the rest of the cell.
Serves as an electron carrier in cellular respiration (ATP production). Activates sirtuins (SIRT1-7), a family of proteins involved in DNA repair, inflammation regulation, and metabolic homeostasis. Also activates PARP enzymes involved in DNA damage repair.
- Neuroprotection and cognitive support
- Metabolic health and insulin sensitivity
- Cardiovascular protection
- Longevity and anti-aging protocols
- Alzheimer's disease research
- Anti-aging and longevity protocols
- Energy and cognitive enhancement
- Addiction recovery support
- Athletic performance and recovery
- Metabolic health optimization
- Very limited human clinical data
- Optimal dosing not established
- Long-term effects unknown
- Injection site reactions
- Interactions with other peptides not well characterized
- IV infusions can cause flushing, nausea, chest tightness (usually transient)
- Oral precursors (NMN, NR) generally well-tolerated
- Long-term effects of supraphysiological dosing unknown
- Theoretical concern: NAD+ may support cancer cell metabolism
- Quality varies significantly across suppliers
Not FDA-approved and not on any compounding list. Available as a research chemical. One of the more scientifically interesting longevity peptides with a growing research base, but human clinical trials are in early stages. Not affected by the 2026 regulatory changes.
NAD+ itself is not FDA-approved as a drug. Injectable NAD+ is available through compounding pharmacies with a prescription. Oral precursors (NMN, NR) are sold as dietary supplements. Not on any FDA compounding category list — exists in a separate regulatory framework from the peptides affected by the 2026 reclassification.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.